Notably, inhibition of GSK-3 reduced tumor budding through necrotic and apoptotic pathways as well as significantly increased activated immune cells to enhance anti-tumor responses compared to PD-L1/PD-1 blockade approaches, suggesting that GSK-3 is involved in the regulation of tumor differentiation in CRC and may be involved in immune evasion mechanisms (Guil-Luna et al. 2023). The gene discussed is CD274; the disease is colorectal carcinoma.